CliffBio
small molecule

NITISINONE

NITISINONE

Loss of exclusivity—loss of exclusivity
CompanyEton Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameNITISINONE
Active ingredientNITISINONE
Strength5MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2023
Marketing statusRX

More from Eton Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

NITISINONE patent cliff — loss of exclusivity — | CliffBio